Aluminum Toxicity Following IV Use of Oral Methadone Solution

REFERENCES

• Alfrey AC, Mishell JM, Burks J, Contiguglia SR, Rudolph H, Lewin E, Holmes JH. Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Organs 1972; 18: 257–61; 266–267
   PubMedGoogle Scholar
• Mahurkar SD, Salta R, Smith EC, Dhar SK, Meyers L, Dunea G. Dialysis dementia. Lancet 1973; 1(7817)1412–1415, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Burks J, Huddlestone J, Lewin E, Alfrey A, Rudolph H. A progressive encephalopathy in chronic dialysis patients. Neurology 1974; 24: 359
   Web of Science ®Google Scholar
• Barratt LJ, Lawrence JR. Dialysis-associated dementia. Aust N Z J Med 1975; 5: 62–65
   PubMedGoogle Scholar
• Platts MM, Hislop JS. Aluminium and dialysis encephalopathy. Lancet 1976; 2(7976)98, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Elliott HL, MacDougall AI, Fell GS. Aluminum toxicity syndrome. Lancet 1978; 1(8075)1203, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DN. Osteomalacic dialysis osteodystrophy: evidence for a water-borne æteiological agent, probably aluminium. Lancet 1978; 1(8069)841–845, [CROSSREF]
   PubMedGoogle Scholar
• Short AI, Winney RJ, Robson JS. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication. Proc Eur Dial Transplant Assoc 1980; 17: 226–233
   PubMedGoogle Scholar
• Wing AJ, Brunner FP, Brynger H, Chantler C, Donckerwolcke RA, Gurland HJ, Jacobs C, Kramer P, Selwood NH. Dialysis dementia in Europe. Lancet 1980; 2(8187)190–192
   PubMed Web of Science ®Google Scholar
• Arze RS, Parkinson IS, Cartlidge NE, Britton P, Ward MK. Reversal of aluminium dialysis encephalopathy after desferrioxamine treatment. Lancet 1981; 2(8255)1116, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pogglitsch H, Petek W, Wawschinek O, Holzer W. Treatment of early stages of dialysis encephalopathy by aluminium depletion. Lancet 1981; 2(8259)1344–1345, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nieboer E, Gibson BL, Oxman AD, Kramer JR. Health effects of aluminum: a critical review with emphasis on aluminum in drinking water. Environ Rev 1995; 3: 29–81
   Google Scholar
• Winship KA. Toxicity of aluminium: a historical review, part 1. Adverse Drug React Toxicol Rev 1992; 11: 123–141
   PubMedGoogle Scholar
• Yokel RA, McNamara PJ. Aluminum toxicokinetics: an updated minireview. Pharmacol Toxicol 2001; 88: 159–167, [CROSSREF]
   PubMedGoogle Scholar
• Pennington JA, Schoen SA. Estimates of dietary exposure to aluminium. Food Addit Contam 1995; 12: 119–128
   PubMed Web of Science ®Google Scholar
• Moore PB, Day JP, Taylor GA, Ferrier IN, Fifield LK, Edwardson JA. Absorption of aluminium-26 in Alzheimer's disease, measured using accelerator mass spectrometry. Dement Geriatr Cogn Disord 2000; 11: 66–69, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nolan CR, DeGoes JJ, Alfrey AC. Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. South Med J 1994; 87: 894–898
   PubMed Web of Science ®Google Scholar
• Slanina P, Frech W, Ekström L-G, Lööf L, Slorach S, Cedergren A. Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem 1986; 32: 539–541
   PubMed Web of Science ®Google Scholar
• Bakir AA, Hryhorczuk DO, Ahmed S, Hessl SM, Levy PS, Spengler R, Dunea G. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol 1989; 31: 40–44
   PubMed Web of Science ®Google Scholar
• Van Landeghem GF, De Broe ME, D’Haese PC. Al and Si: their speciation, distribution, and toxicity. Clin Biochem 1998; 31: 385–397, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Spence PS. Aluminum and its compounds. Experimental and clinical neurotoxicology2nd, PS Spencer, HH Schaumberg. Oxford University Press, New York 2000; 142–151
   Google Scholar
• Yokel RA. Brain uptake, retention, and efflux of aluminum and manganese. Environ Health Perspect 2002; 110(Suppl 5)699–704
   PubMed Web of Science ®Google Scholar
• Yokel RA. Aluminum chelation principles and recent advances. Coord Chem Rev 2002; 228: 97–113, [CROSSREF]
   Web of Science ®Google Scholar
• Van Landeghem GF, D’Haese PC, Lamberts LV, Barata JD, DeBroe ME. Aluminium speciation in cerebrospinal fluid of acutely aluminium intoxicated dialysis patients before and after desferrioxamine treatment; a step in the understanding of the element's neurotoxicity. Nephrol Dial Transplant 1997; 12: 1692–1698, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome, possible aluminum intoxication. New Engl J Med 1976; 294: 184–188
   PubMed Web of Science ®Google Scholar
• Berend K, van der Voet GB, de Wolff FA. Acute aluminum intoxication. Structure and Bonding 2002; 104: 1–58
   Web of Science ®Google Scholar
• Hémadi M, Miquel G, Kahn PH, Chahine J-M. Aluminum exchange between citrate and human serum transferrin and interaction with transferrin receptor 1. Biochemistry 2003; 42: 3120–3130, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Greger JL, Sutherland JE. Aluminum exposure and metabolism. Crit Rev Clin Lab Sci 1997; 34: 439–474
   PubMed Web of Science ®Google Scholar
• Yokel RA, Wilson M, Harris WR, Halestrap AP. Aluminum citrate uptake by immortalized brain endothelial cells: implications for its blood-brain barrier transport. Brain Res 2002; 930: 101–110, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yokel RA, Allen DD, Ackley DC. The distribution of aluminum into and out of the brain. J Inorg Biochem 1999; 76: 127–132, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Perl DP, Good PF. Uptake of aluminium into central nervous system along nasal-olfactory pathyways. Lancet 1987; 1(8540)1028, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Divine KK, Lewis JL, Grant PG, Bench G. Quantitative particle-induced X-ray emission imaging of rat olfactory epithelium applied to the permeability of rat epithelium to inhaled aluminum. Chem Res Toxicol 1999; 12: 575–581, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Monteagudo FS, Cassidy MJ, Folb PI. Recent developments in aluminium toxicology. Med Toxicol 1989; 4: 1–16
   Google Scholar
• Winship KA. Toxicity of aluminium: a historial review, part 2. Adverse Drug React Toxicol Rev 1993; 12: 177–211
   PubMedGoogle Scholar
• Cannata-Andía JB, Fernádez-Martin JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant 2002; 17(Suppl 2)9–12
   PubMedGoogle Scholar
• Priest ND, Newton D, Day JP, Talbot RJ, Warner AJ. Human metabolism of aluminum-26 and gallium-67 injected as citrates. Hum Exp Toxicol 1995; 14: 287–293
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Jäger DE, Ohnesorge FK. Aluminum toxicokinetics. Pharmacol Toxicol 1990; 66: 4–9
   PubMedGoogle Scholar
• De Voto E, Yokel RA. The biological speciation and toxicokinetics of aluminum. Environ Health Perspect 1994; 102: 940–951
   PubMed Web of Science ®Google Scholar
• Cannata-Andía JB. Adynamic bone and chronic renal failure: an overview. Am J Med Sci 2000; 320: 81–84, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dainiak N. Hematologic complications of renal disease. Hematology basic principles and practice3^rd, R Hoffman, EJ Benz, SJ Shuttil, B Furie, HJ Cohen, LE Silberstein, P McGlave. Churchill Livingstone, New York 2000; 2357–2373
   Google Scholar
• Macdougall IC, Eckardt K-U. Haematological disorders. Oxford textbook of clinical nephrology2^nd, AM Davison, JS Cameron, J-P Grünfeld, DN Kem, E Ritz, CG Winearls. Oxford Medical Publications, OxfordEngland 1998; 1935–1954
   Google Scholar
• Smith EC, Mahurkar SD, Mamdani BH, Dunea G. Diagnosing dialysis dementia. Dial Transplant 1978; 7: 1264, 1266, 1274
   Web of Science ®Google Scholar
• Rosenbek JC, McNeil MR, Lemme ML, Prescott TE, Alfrey AC. Speech and language findings in a chronic hemodialysis patient: a case report. J Speech Hearing Dis 1975; 40: 245–252
   PubMedGoogle Scholar
• Donaghy M, Compston A, Rossor M, Warlow C. Clinical diagnosis. Brain's diseases of the nervous system11^th, M Donaghy. Oxford University Press, OxfordEngland 2001; 1–59
   Google Scholar
• Madison DP, Baehr ET, Bazell M, Hartman RW, Mahurkar SD, Dunea G. Communicative and cognitive deterioration in dialysis dementia: two case studies. J Speech Hear Disord 1977; 42: 238–246
   PubMedGoogle Scholar
• Mahurkar SD, Meyers L, Cohen J, Kamath RV, Dunea G. Electroencephalographic and radionuclide studies in dialysis dementia. Kidney Int 1978; 13: 306–315
   PubMed Web of Science ®Google Scholar
• Sherrard DJ. Renal osteodystrophy. Principles and practice of dialysis3^rd, WL Henrick. Lippincott Williams & Wilkins, , Philadelphia 2004; 381–392
   Google Scholar
• Jeffery EH, Abreo K, Burgess E, Cannata J, Greger JL. Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. J Toxicol Environ Health 1996; 48: 649–665, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kanwar VS, Jenkins JJ, Mandrell BN, Furman WL. Aluminum toxicity following intravesical alum irrigation for hemorrhagic cystitis. Med Pediatr Oncol 1996; 27: 64–67, [CROSSREF]
   PubMedGoogle Scholar
• Phelps KR, Naylor K, Brien TP, Wilbur H, Haqqie SS. Encephalopathy after bladder irrigation with alum: case report and literature review. Am J Med Sci 1999; 318: 181–185, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Murphy CP, Cox RL, Harden EA, Stevens DA, Heye MM, Herzig RH. Encephalopathy and seizures induced by intravesical alum irrigations. Bone Marrow Transplant 1992; 10: 383–385
   PubMed Web of Science ®Google Scholar
• Nakamura H, Rose PG, Blumer JL, Reed MD. Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis. J Clin Pharmacol 2000; 40: 296–300, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hantson P, Mahieu P, Gersdorff M, Sindic CJ, Lauwerys R. Encephalopathy with seizures after use of aluminium-containing bone cement. Lancet 1994; 344(8937)1647, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Renard JL, Felten D, Béquet D. Post-otoneurosurgery aluminium encephalopathy. Lancet 1994; 344(8914)63–64, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Reusche E, Pilz P, Oberascher G, Lindner B, Egensperger R, Gloeckner K, Trinka E, Iglseder B. Subacute fatal aluminum encephalopathy after reconstructive otoneurosurgery: a case report. Hum Pathol 2001; 32: 1136–1140, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Berend K, van der Voet G, Boer WH. Acute aluminum encephalopathy in a dialysis center caused by a cement mortar water distribution pipe. Kidney Int 2001; 59: 746–753
   PubMed Web of Science ®Google Scholar
• Kavoussi LR, Gelstein LD, Andriole GL. Encephalopathy and an elevated serum aluminum level in a patient receiving intravesical alum irrigation for severe urinary hemorrhage. J Urol 1986; 136: 665–667
   PubMed Web of Science ®Google Scholar
• Seear MD, Dimmick JE, Rogers PC. Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis. Urology 1990; 36: 353–354, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moreno A, Dominguez P, Dominquez C, Bullabriga A. High serum aluminium levels and acute reversible encephalopathy in a 4-year-old boy with acute renal failure. Eur J Pediatr 1991; 150: 513–514, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shoskes DA, Radzinski CA, Struthers NW, Honey RJ. Aluminum toxicity and death following intravesical alum irrigation in a patient with renal impairment. J Urol 1992; 147: 697–699
   PubMed Web of Science ®Google Scholar
• Sing K, Ahmed S, Moneer Y, Johnson B, Erickson T, Hryhorczuk D. Hyperaluminemia following bladder irrigation with alum: a case report. Vet Human Toxicol 1993; 35: 340
   Google Scholar
• Perazella M, Brown E. Acute aluminum toxicity and alum bladder irrigation in patients with renal failure. Am J Kidney Dis 1993; 21: 44–46
   PubMed Web of Science ®Google Scholar
• Sedman AB, Miller NL, Warady BA, Lum GM, Alfrey AC. Aluminum loading in children with chronic renal failure. Kidney Int 1984; 26: 201–204
   PubMed Web of Science ®Google Scholar
• Zatta P, Zambenedetti P, Reusche E, Stellmacher F, Cester A, Albanese P, Meneghel G, Nordio M. A fatal case of aluminum encephalopathy in a patient with severe chronic renal failure not on dialysis. Nephrol Dial Transplant 2004; 19: 2929–2931, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bakir AA, Hryhorczuk DO, Berman E, Dunea G. A fatal case of aluminum encephalopathy in a patient with severe chronic renal failure not on dialysis. Nephrol Dial Transplant 1986; 32: 171–176
   Google Scholar
• Kirschbaum BB, Schoolwerth AC. Aoral cute aluminum toxicity associated with citrate and aluminum containing antacids. Am J Med Sci 1989; 297: 9–11
   PubMed Web of Science ®Google Scholar
• Campistol JM, Cases A, Botey A, Revert A. Acute encephalopathy in an uremic patient. Nephron 1989; 51: 103–106
   PubMed Web of Science ®Google Scholar
• Domingo JL. The use of chelating agents in the treatment of aluminum overload. Clin Toxicol 1989; 27: 355–367
   Web of Science ®Google Scholar
• Ackrill P, Ralston AJ, Day JP. Role of desferrioxamine in the treatment of dialysis encephalopathy. Kidney Int 1986; 29(Suppl 18)S104–S107
   Google Scholar
• De Broe ME, D’Haese PC, Couttenye MM, Van Landeghem GF, Lamberts LV. New insights and strategies in the diagnosis and treatment of aluminium overload in dialysis patients. Nephrol Dial Transplant 1993; 8(Suppl 1)47–50
   PubMedGoogle Scholar
• Ackrill P, Ralston AJ, Day JP, Hodge KC. Successful removal of aluminium from patient with dialysis encephalopathy. Lancet 1980; 2(8196)692–693, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Parajón JP, González EB, Cannata JB, Medel AS. A critical appraisal of the speciation of aluminum in serum by ultrafiltration. Trace Elem Med 1989; 6: 41–46
   Web of Science ®Google Scholar
• Canteros A, Diaz-Corte C, Fernandez-Martin JL, Gago E, Fernandez-Merayo C, Cannata J. Ultrafiltratable aluminium after very low doses of desferrioxamine. Nephrol Dial Transplant 1998; 13: 1538–1542, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yokel RA, Rhineheimer SS, Sharma P, Elmore D, McNamara PJ. Entry, half-life, and desferrioxamine-acclerated clearance of brain aluminum after a single 26Al exposure. Toxicol Sci 2001; 64: 77–82
   PubMed Web of Science ®Google Scholar
• Verpooten GA, D’Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 1992; 7: 931–938
   PubMed Web of Science ®Google Scholar
• De Broe ME, Drüeke TB, Ritz E. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant 1993; 8(Suppl 1)1–4
   Google Scholar
• Jorge C, Gil C, Possante M, Catarino MC, Cruz A, Andrade R, Teixeira R, Santos N, Ferreira A. Use of a desferrioxamine “microdose” to chelate aluminum in hemodialysis patients. Clin Nephrol 1999; 52: 335–336
   PubMed Web of Science ®Google Scholar
• Russo LS, Beale G, Sandroni S, Ballinger WE. Aluminium intoxication in undialysed adults with chronic renal failure. J Neurol Neurosurg Psychiatry 1992; 55: 697–700
   PubMed Web of Science ®Google Scholar
• McCauley J, Sorkin MI. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant 1989; 4: 110–114
   PubMed Web of Science ®Google Scholar
• Sherrard DJ, Walker JV, Boykin JL. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. Am J Kidney Dis 1988; 12: 126–130
   PubMed Web of Science ®Google Scholar
• Lillevang ST, Pedersen FB. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant 1989; 4: 676
   PubMed Web of Science ®Google Scholar
• Barata JD, D’Haese PC, Pires C, Lamberts LV, Simoes J, De Broe ME. Low-dose (5mg/kg) desferrioxamine treatment in acutely aluminiumintoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant 1996; 11: 125–132
   PubMed Web of Science ®Google Scholar
• Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Safety 1997; 17: 407–421
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Buncic R, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman MH. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. New Engl J Med 1986; 314: 869–873
   PubMed Web of Science ®Google Scholar
• Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989; 73: 403–409
   PubMed Web of Science ®Google Scholar
• Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983; 2(8343)181–184, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Robins-Browne RM, Prpic JK. Desferrioxamine and systemic yersiniosis. Lancet 1983; 2(8363)1372, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gallant T, Freedman MH, Vellend H, Francombe VH. Yersinia sepsis in patients with iron overload treated with deferoxamine. New Engl J Med 1986; 314: 1643
   PubMed Web of Science ®Google Scholar
• Boelaert JH, Vergauwe PL, Vandepitte JM. Mucormycosis infection in dialysis patients. Ann Intern Med 1987; 107: 782–783
   PubMed Web of Science ®Google Scholar
• Boelaert JH, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18: 660–667
   PubMed Web of Science ®Google Scholar
• Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IY. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992; 339(8795)699–701, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Koren G, Bentu Y, Strong D, Harvey E, Klein J, Baumal R, Spielberg SP, Freedman MH. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1989; 143: 1077–1080
   PubMedGoogle Scholar
• Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Int J Hematol 1991; 54: 371–375
   PubMed Web of Science ®Google Scholar
• Veis JH, Contiguglia R, Klein M, Mishell J, Alfrey AC, Shapiro JI. Mucormycosis in deferoxamine-treated patients on dialysis. Ann Intern Med 1987; 107: 258
   PubMed Web of Science ®Google Scholar
• Goodill JJ, Abuelo JG. Mucormycosis – a new risk of deferoxamine therapy in dialysis patients with aluminum or iron overload?. New Engl J Med 1987; 317: 54
   PubMed Web of Science ®Google Scholar
• Rubinstein M, Dupont P, Doppee JP, Dehon C, Ducobu J, Hainaut J. Ocular toxicity of desferrioxamine. Lancet 1985; 1(8432)817–818, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cases A, Kelly J, Sabater J, Campistol JM, Torras A, Montoliu J, López I, Revert L. Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Clin Nephrol 1988; 29: 176–178
   PubMed Web of Science ®Google Scholar
• Cannata JB, Serrano M, Fernandez Soto I, Fernandez Martin JL, Olaizola IR. Minimizing the risk of oral aluminium exposure in chronic renal failure. Contrib Nephrol 1989; 71: 81–89
   PubMedGoogle Scholar
• Müller JP, Steinegger A, Schlatter C. Contribution of aluminium from packaging materials and cooking utensils to the daily aluminium intake. Z Lebensm Unters Forsch 1993; 197: 332–341, [CROSSREF]
   PubMedGoogle Scholar
• Liukkonen-Lilja H, Piepponen S. Leaching of aluminium from aluminium dishes and packages. Food Addit Contam 1992; 9: 213–223
   PubMed Web of Science ®Google Scholar
• Lin J-L, Yang Y-J, Yang S-S, Leu M-L. Aluminum utensils contribute to aluminum accumulation in patients with renal disease. Am J Kidney Dis 1997; 30: 653–658
   PubMed Web of Science ®Google Scholar
• Greger JL, Goetz W, Sullivan D. Aluminum levels in foods cooked and stored in aluminum pans, trays and foil. J Food Prot 1985; 48: 772–777
   PubMed Web of Science ®Google Scholar
• Humeniuk R, Ali R, McGregor C, Darke S. Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction 2003; 98: 413–418, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Darke S, Ross J, Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug Alcohol Depend 1996; 43: 191–198, [CROSSREF]
   PubMed Web of Science ®Google Scholar